Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

Medibank Private shares took a big hit nearly 3 years ago due to the infamous cyber breach. Investors who chose to buy the dip and have held ever since have done quite well - shares rallied 80% in the following 3 years. But shares have fallen over 12% since August, when it released its FY25 results.…

ByNick SundichDecember 11, 2025

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Rhythm Biosciences (ASX: RHY) may finally be turning the corner. The company has secured NHS expertise to support its ColoSTAT bowel cancer blood test launch in the UK, while a separate deal with Catch Bio expands its geneType platform across the United States. For a stock trading at just A$25 to A$30 million market cap,…

ByUjjwal MaheshwariDecember 11, 2025

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first surgical case in the region and a strong debut at the Hong Kong Orthopaedic Association's 45th Annual Congress. For investors, this milestone shows the company…

ByUjjwal MaheshwariDecember 11, 2025

4DMedical’s Growth Story Gains Airflow in the US Market

4DMedical Finds Its Rhythm 4DMedical (ASX:4DX) climbed 9% today as the company continues to build strong commercial momentum with its CT:VQ lung imaging technology. Following FDA clearance in September, 4DMedical’s entry into the US market is beginning to gain real traction. The latest partnership with the University of Miami adds another major institution to its…

ByCharlie YouldenDecember 10, 2025

Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact

Cogstate’s H1 Hit Is a Timing Story, Not a Demand Story Cogstate Ltd (ASX:CGS) delivered a business update this morning that reset expectations for its H1 FY26 revenue timing and margin outlook, which triggered a sharp 22% sell-off. The market reacted to near-term revenue being pushed into the back half of the year due to…

ByCharlie YouldenDecember 10, 2025

Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s

Immutep Lands Global Deal With Dr. Reddy’s Immutep (ASX:IMM) surged 23% at market open after announcing a new strategic partnership through a collaboration and licensing agreement with Dr Reddys Laboratories, a major global pharmaceutical company based in India. Under the deal, Dr Reddys secures exclusive rights to develop and commercialise Efti across all markets outside…

ByCharlie YouldenDecember 9, 2025

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others will be demoted. It is important to note from the outset the June and December rebalances only involve the ASX 50, ASX 100 and ASX 200 indices whilst the March and September rebalances also involve…

ByNick SundichDecember 9, 2025

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

TLX Delivers Clinical Progress It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet period, especially following recent market nerves around the FDA slowdown and a few ASX announcement missteps. Today, the company reported an important milestone in its PROSTACT Global Phase 3 trial, confirming that the first patient…

ByCharlie YouldenDecember 8, 2025

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

The tables have turned, and shareholders face a key decision as the 10 December deadline approaches. Mayne Pharma (ASX: MYX) has turned the tables on US suitor Cosette Pharmaceuticals, issuing a termination notice alleging "wilful and intentional" breaches of their A$672 million takeover agreement. The Adelaide-based company, which spent much of 2025 fighting Cosette's attempts…

ByUjjwal MaheshwariDecember 5, 2025

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in an otherwise quiet year for ASX biotech debuts. Unlike most life sciences IPOs that arrive with little more than clinical-stage promise, Saluda Medical already generates US$70 million in annual revenue and is targeting US$82 million…

ByUjjwal MaheshwariDecember 4, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Medibank Private shares have recovered the losses after the cyber breach 2 years ago, but what’s next?

Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

4DMedical’s Growth Story Gains Airflow in the US Market

Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact

Immutep (ASX:IMM) Surges on US$369M Global Partnership With Dr. Reddy’s

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?

Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here